Increased percentages of CD49f expressing CD133+ CTCs were found in patients with vulvar cancer after aRT (Fig. 3E; dark orange dots) as well as in patients with cervical cancer after aCRT (Fig. 3F; dark blue dots) and pCRT (dark red dots) in comparison to pre-therapeutic stages. Here, PROM1 is linked to cervical cancer.